Home > > Europe And Global Viral Conjunctivitis Pipeline Drugs Market- Size, Share, Growth Rate, and Forecast
The Europe Viral Conjunctivitis Pipeline Drugs market was valued at $906.5 Million in 2023, and is projected to reach $1,118.8 Million by 2030 growing at a CAGR of 3.10% from 2024 to 2030. DST-100 segment is expected to be the highest contributor to this market, with $580.0 Million in 2023, and is anticipated to reach $681.7 by 2030, registering a CAGR of 2.38%. APD-209 segment is anticipated to reach $437.2 Million by 2030 with the highest CAGR of 4.30%. Drug Type DST-100 APD-209 BY REGION North America U.s. Canada Europe Germany U.k. France Italy Spain Rest of Europe Asia China Japan South Korea India Singapore Rest of Asia Middle East & Africa Brazil Mexico South Africa Australia Rest of MENA